A new one-a-day-pill holds promise for HIV's 'forgotten population'

It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's ...
The Malaysian Reserve

FDA approves Novo Nordisk’s Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short Stature (ISS), born Small for Gestational ...